Medication info
Alobon Plus D Tablet

Alobon Plus D Tablet

Prescription medicationTabletOral
Ingredient · strength
Sodium Alendronate Trihydrate›91.37mg / 1 tabletCholecalciferol Concentrate Powder›53.33mg / 1 tablet
Manufacturer / importer
Daehan New Pharm Co., Ltd.
Appearance
White to grayish-white rectangular tablets
Packaging
4 tablets (4 tablets/PTP X 1)
Approval status
Active

MFDS item code 201508499 · Approved 2015.12.30 · Insurance code 669906530

Summary

Main use
Treatment of osteoporosis in postmenopausal women and men
Who takes it
Adults · Children
Adult dose
Take 1 tablet of this medicine (70 mg/2800 IU or 70 mg/5600 IU) once weekly in the morning with plenty of water, at least 30 minutes before consuming food, beverages, or other medicines (see General Precautions). The appropriate dose for most patients with osteoporosis is 70 mg/5600 IU once weekly. The appropriate treatment duration has not been established. The safety and efficacy of this medicine for the treatment of osteoporosis are based on 4 years of clinical data. The need for continued treatment should be reviewed regularly in all patients receiving bisphosphonates. Patients at low risk of fracture should be considered for discontinuation after taking the medicine for 3~5 years. Patients who discontinue treatment should be reassessed regularly for fracture risk. Other beverages or food, including mineral water and barley tea, and medicines may reduce alendronate absorption (see Interactions). Consuming food within 30 minutes after taking this medicine or at the same time may reduce alendronate absorption in the body and reduce its effect. Take this medicine as soon as you get up in the morning, swallowing it with plenty of water (170∼230 mL) to ensure rapid passage to the stomach and reduce the possibility of esophageal irritation. Do not lie down for at least 30 minutes after taking it and until after the first food intake. Do not take this medicine at bedtime or before getting up. Failure to follow these instructions may increase the risk of esophageal adverse reactions (see Warnings and General Precautions). Patients with inadequate calcium and vitamin D intake from food should take supplements (see Precautions for Use, 4. General Precautions, 2) Information to be provided to patients (4)). Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, patients with chronic illness) may need additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndrome may need higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. This medicine provides a weekly amount equivalent to daily doses of 400 IU and 800 IU of vitamin D when taken once weekly. If a patient taking 1 tablet of this medicine forgets to take it on the scheduled day, take 1 tablet the next morning, resume taking it on the originally scheduled day, and thereafter take it regularly once weekly. However, do not take 2 tablets on the same day. ○ Administration to elderly patients (65 years of age and older): No dose adjustment is necessary. ○ Administration to patients with renal impairment: No dose adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance 35∼60 mL/min); however, use of this medicine is not recommended in patients with severe renal impairment (creatinine clearance below 35 mL/min) because there is insufficient clinical experience.
Child dose
○ Children and adolescents (under 18 years of age): Safety and efficacy in children and adolescents have not been established.

Ingredients

Manufacturer
Daehan New Pharm Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women and men

  • Osteoporosis
View approved original text

This medication is used to treat osteoporosis in postmenopausal women and men.

How to take

Adult dose

Take 1 tablet of this medicine (70 mg/2800 IU or 70 mg/5600 IU) once weekly in the morning with plenty of water, at least 30 minutes before consuming food, beverages, or other medicines (see General Precautions). The appropriate dose for most patients with osteoporosis is 70 mg/5600 IU once weekly. The appropriate treatment duration has not been established. The safety and efficacy of this medicine for the treatment of osteoporosis are based on 4 years of clinical data. The need for continued treatment should be reviewed regularly in all patients receiving bisphosphonates. Patients at low risk of fracture should be considered for discontinuation after taking the medicine for 3~5 years. Patients who discontinue treatment should be reassessed regularly for fracture risk. Other beverages or food, including mineral water and barley tea, and medicines may reduce alendronate absorption (see Interactions). Consuming food within 30 minutes after taking this medicine or at the same time may reduce alendronate absorption in the body and reduce its effect. Take this medicine as soon as you get up in the morning, swallowing it with plenty of water (170∼230 mL) to ensure rapid passage to the stomach and reduce the possibility of esophageal irritation. Do not lie down for at least 30 minutes after taking it and until after the first food intake. Do not take this medicine at bedtime or before getting up. Failure to follow these instructions may increase the risk of esophageal adverse reactions (see Warnings and General Precautions). Patients with inadequate calcium and vitamin D intake from food should take supplements (see Precautions for Use, 4. General Precautions, 2) Information to be provided to patients (4)). Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, patients with chronic illness) may need additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndrome may need higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. This medicine provides a weekly amount equivalent to daily doses of 400 IU and 800 IU of vitamin D when taken once weekly. If a patient taking 1 tablet of this medicine forgets to take it on the scheduled day, take 1 tablet the next morning, resume taking it on the originally scheduled day, and thereafter take it regularly once weekly. However, do not take 2 tablets on the same day. ○ Administration to elderly patients (65 years of age and older): No dose adjustment is necessary. ○ Administration to patients with renal impairment: No dose adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance 35∼60 mL/min); however, use of this medicine is not recommended in patients with severe renal impairment (creatinine clearance below 35 mL/min) because there is insufficient clinical experience.

Child dose

○ Children and adolescents (under 18 years of age): Safety and efficacy in children and adolescents have not been established.

Precautions

This drug may irritate the gastrointestinal mucosa, leading to esophageal adverse reactions such as esophagitis, esophageal ulcers, and esophageal erosion. If symptoms of esophageal irritation occur, discontinue use immediately and consult a doctor. Take this medication with a sufficient amount of water, and do not lie down for at least 30 minutes after taking it to reduce the risk of esophageal irritation. Patients with esophageal discharge disorders or those who cannot sit or stand up straight for more than 30 minutes, patients allergic to any component of this drug, patients with hypocalcemia, and patients with specific genetic metabolic disorders should not take this medication. Adverse reactions such as gastrointestinal discomfort, abdominal pain, nausea, dyspepsia, musculoskeletal pain, headache, dizziness, and skin rash may occur during treatment; if symptoms are severe, consult a doctor. This drug can interfere with the absorption when taken along with calcium supplements or antacids, so there should be at least a 30-minute interval between doses. Care should be taken when using it in conjunction with aspirin or non-steroidal anti-inflammatory drugs as gastrointestinal adverse reactions may increase. Women who are pregnant or breastfeeding should be cautiously administered based on a doctor's judgment, and it is not recommended for children. It is not recommended for patients with severely impaired renal function. If calcium and vitamin D are deficient during treatment, it is advised to take supplements, and patients should be fully informed of the correct method of administration and precautions. In case of overdose, hypocalcemia and gastrointestinal irritation may occur, so consult medical personnel immediately, and do not induce vomiting but keep the patient upright. This medication should be kept out of the reach of children and should not be transferred to another container.

Side effects

Esophagitis, esophageal ulcer, esophageal erosion, esophageal obstruction, esophageal perforation, bleeding, dysphagia, odynophagia, retrosternal pain, heartburn, abdominal pain, nausea, dyspepsia, constipation, diarrhea, flatulence, acid reflux, esophageal ulcer, vomiting, abdominal distension, gastritis, musculoskeletal (bone, muscle, or joint) pain, muscle cramps, headache, dizziness, taste disturbances, rash, erythema, anastomotic ulcer, urticaria, angioedema, myalgia, malaise, asthenia, fever, symptoms of hypocalcemia, peripheral edema, esophageal erosion, esophageal stenosis, oropharyngeal ulcer, gastric ulcer, duodenal ulcer, localized jawbone necrosis, joint swelling, low-energy fractures of the femoral neck and other bones, dizziness, vertigo, itching, hair loss, Stevens-Johnson syndrome, toxic epidermal necrolysis, uveitis, scleritis, episcleritis, cholesteatoma of the external auditory canal, nasopharyngitis

Not everyone experiences these, and they can vary from person to person.

Storage

This drug is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, avoid direct sunlight and store at room temperature between 1 to 30 degrees Celsius. This will help maintain the effectiveness of the drug for a longer period.

Appearance and packaging

Appearance

White to grayish-white rectangular tablets

Package unit

4 tablets (4 tablets/PTP X 1)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.